Publications by authors named "Vilar-Compte D"
Article Synopsis
- Patients with cancer have a higher risk of developing infective endocarditis (IE), which can lead to worse health outcomes.
- A retrospective study conducted in Mexico City from 2006 to 2022 matched 36 cancer patients with 72 controls without cancer to identify factors related to IE.
- Key risk factors for IE in cancer patients included obesity, recent surgery, and invasive procedures, with S. aureus infections linked to a higher incidence of systemic embolization, although mortality rates were similar between both groups.
Objectives: Vaccination is the best preventive measure for SARS-CoV-2 infection; however, efficacy is lower in cancer patients. During the pandemic period, Mexico was characterized by the use of seven different COVID-19 vaccine platforms, and oncologic patients were not prioritized for vaccination. We report the outcomes of COVID-19 in cancer patients after the beginning of the national vaccine campaign in Mexico.
View Article and Find Full Text PDFMulticenter study on infections in Mexico: exploring the landscape.
Infect Control Hosp Epidemiol
October 2024
Article Synopsis
- - The study examined Clostridioides difficile infection (CDI) trends and outcomes in 16 healthcare facilities in Mexico from 2016 to 2022, focusing on patient demographics and clinical data.
- - Out of 2,356 CDI cases identified, 90% were healthcare-associated, with common comorbidities including hypertension and diabetes; the 30-day mortality rate was 16%.
- - The findings highlight the need for improved surveillance and standardized CDI classification in Mexico, noting stable rates but differences in incidence between public and private hospitals.
Introduction:: Patients with thoracic cancers have one of the highest mortality rates among patients with cancer and COVID-19. Data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are confined to heterogenous studies with limited follow-up data. We leveraged data from the COVID-19 and Cancer Consortium (CCC19) (NCT04354701) to analyze the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 in patients with thoracic cancers.
View Article and Find Full Text PDFPseudomonas fluorescens CRBSI outbreak: complying with the standardization of invasive procedures is a step ahead in the fight against antimicrobial resistance.
Antimicrob Resist Infect Control
April 2024
In the healthcare sector, the implementation of standardized procedures, such as those commonly employed in franchises to ensure consistent quality, remains underprioritized. Within this framework, we focus on the importance of standardized central venous catheter (CVC) insertion procedures to prevent healthcare-associated outbreaks. While antimicrobial resistance (AMR) may still not be the most prevalent problem in some institutions, its increasing significance certainly underlines the urgency of infection prevention.
View Article and Find Full Text PDFArticle Synopsis
- COVID-19 severely impacts cancer patients, particularly those with metastatic cancer, and this study explored the relationship between cancer metastasis and COVID-19 outcomes.
- Using data from the CCC19 registry, researchers analyzed over 10,000 cancer patients with COVID-19 to assess hospitalization rates and mortality based on the presence and site of metastasis.
- Findings showed that patients with metastases had higher hospitalization rates (59% vs. 49%) and 30-day mortality (18% vs. 9%), with those having lung metastases experiencing the highest risk of death in that timeframe.
Background: Health care workers (HCWs) are occupationally exposed to severe acute respiratory syndrome coronavirus (SARS-CoV-2). This study aimed to characterize COVID-19 in HCWs at an oncology hospital in Mexico City over 2-years, identify factors associated with severity, and establish transmission dynamics.
Methods: This retrospective study included HCWs with confirmed COVID-19.
Article Synopsis
- Vaccination significantly reduces SARS-CoV-2-related illness, but there's still uncertainty about how cancer patients' immune responses work after vaccination.
- This study compared the antibody responses to the BNT162b2 and AZD122 vaccines in cancer patients and healthcare workers, revealing differences in antibody levels between the two groups.
- The results indicated that the BNT162b2 vaccine led to stronger antibody responses, but active cancer patients had a tougher time developing high antibody levels, highlighting the need for tailored vaccination strategies for immunosuppressed individuals.
Cancer patients with infection (CDI) are at a higher risk for adverse outcomes. In addition, a high prevalence of asymptomatic colonization (CDAC) has been reported in this vulnerable population. The molecular characteristics and potential role of CDAC in healthcare-related transmission in the cancer population have been poorly explored.
View Article and Find Full Text PDFImportance: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking.
Objective: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer.
Design, Setting, And Participants: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection.
Background: COVID-19 is associated with systemic inflammation. This inflammatory response is further deregulated by oncological treatments increasing mortality in this population. However, there is conflicting information regarding the clinical factors that increase mortality in patients with severe COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- A study examined outcomes of cancer patients who got COVID-19, focusing on those with and without existing cardiovascular disease (CVD) or risk factors (CVRF).
- The research found that over half of the 10,876 patients had CVD/CVRF, which linked to more severe COVID-19 symptoms and complications.
- Notably, patients without recent cancer treatment experienced worse COVID-19 severity related to CVD/CVRF compared to those under active treatment.
Objective: Hospital-acquired infection (HAI) rates were negatively affected by the the coronavirus disease 2019 (COVID-19) pandemic. We describe the incidence of HAIs, main pathogens, and multidrug-resistant organisms (MDROs) isolated in cancer patients before and during the pandemic.
Design: This retrospective, comparative study included patients with HAIs.
Background: Pancreaticoduodenectomy is the standard treatment for resectable periampullary cancer. Surgical site infections (SSI) are common complications with increased morbidity. The study aimed to describe the prevalence, risk factors, microbiology, and outcomes of SSI among patients undergoing pancreaticoduodenectomy.
View Article and Find Full Text PDFBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) is the most transmissible ß-coronavirus in history, affecting all population groups. Immunocompromised patients, particularly cancer patients, have been highlighted as a reservoir to promote accumulation of viral mutations throughout persistent infection.
Case Presentation: We aimed to describe the clinical course and SARS-CoV-2 mutation profile for 102 days in an immunocompromised patient with non-Hodgkin's lymphoma and COVID-19.
Purpose: There are currently no standard definitions for assessing the severity of Clostridioides difficile infection (CDI) in cancer patients. We evaluated the performance of scoring systems for severity and analyzed risk factors for mortality in a cancer cohort.
Methods: We conducted an observational study in patients with cancer and CDI.
Lawsuits due to patient perception of inappropriate medical actions are a growing reality in medical practice, which entails widespread concern in the medical community. Lawsuits often entail additional circumstances beyond the primary concern of preventing or sanctioning acts of medical negligence. CETREMI proposes various recommendations aimed at legal and medical professionals to improve this circumstance and avoid harming the doctor-patient relationship.
View Article and Find Full Text PDFPurposes: Patients with hematologic malignancies (HM) are among the individuals with highest risk of COVID-19 complications. We report the impact of remdesivir in patients with hematologic malignancies (HM) during Omicron in Mexico City.
Methods: All patients with HM and COVID-19 during December 2021-March 2022 were included.
Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021.